The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." https://aoifetbga909819.blogolenta.com/37151511/elite-investor-pharma-the-risky-wager